相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade
Elizabeth Gavioli et al.
SUPPORTIVE CARE IN CANCER (2017)
WHEN HYDROMORPHONE IS NOT WORKING, TRY LORATADINE: AN EMERGENCY DEPARTMENT CASE OF LORATADINE AS ABORTIVE THERAPY FOR SEVERE PEGFILGRASTIM-INDUCED BONE PAIN
Katherine Moore et al.
JOURNAL OF EMERGENCY MEDICINE (2017)
Patient-Reported Outcomes - Harnessing Patients' Voices to Improve Clinical Care
Ethan Basch
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice
Jeffrey Crawford et al.
Journal of the National Comprehensive Cancer Network (2017)
Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients
Pamala A. Pawloski et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials
Ethan Basch et al.
CLINICAL THERAPEUTICS (2016)
Adverse event reporting in oncology clinical trials - lost in translation?
Shanthi Sivendran et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments
Massimo Di Maio et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report
Cristina Romeo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
The five Ws for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)
Matteo Lambertini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma
Wendy J. Langeberg et al.
SUPPORTIVE CARE IN CANCER (2014)
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
Eva Culakova et al.
CANCER MEDICINE (2014)
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting
Gary H. Lyman et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Patient reported outcome measures could help transform healthcare
Nick Black
BMJ-BRITISH MEDICAL JOURNAL (2013)
A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia
Brian Dulisse et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base
Jeffrey J. Kirshner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Naproxen reduces chemotherapy and pegfilgrastim-induced sleep disturbance possibly mediated through reduced bone pain
J. Gewandter et al.
JOURNAL OF PAIN (2012)
Reliability of adverse symptom event reporting by clinicians
Thomas M. Atkinson et al.
QUALITY OF LIFE RESEARCH (2012)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
A phase II study of loratidine (L) to prevent pegfilgrastim-induced pain (PIP)
J. J. Kirshner et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study
M. Blane Schilling et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2011)
Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients
J. J. Kirshner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The Missing Voice of Patients in Drug-Safety Reporting
Ethan Basch
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study
Ruth Pettengell et al.
SUPPORTIVE CARE IN CANCER (2008)
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy
J Crawford
PHARMACOTHERAPY (2003)
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
RCF Leonard et al.
BRITISH JOURNAL OF CANCER (2003)
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis
GH Lyman et al.
AMERICAN JOURNAL OF MEDICINE (2002)
分享论文
